IMM 1.45% 34.0¢ immutep limited

Let's go back to 2018 for look at my favorite video This should...

  1. 264 Posts.
    lightbulb Created with Sketch. 147
    Let's go back to 2018 for look at my favorite video
    This should have gotten an academy award. Proving something works takes time.

    Now in the last month we have two announcements that eftilagimod can salvage previous refractory patients treated with pembrolizumab and combination therapy with pembrolizumab is really effective.

    What's next?
    Merck announces another FDA fast tract study using pembrolizumab with eftilagimod as first line treatment for NSCLC.
    Followed by a pembrolizumab and eftilagimod AIPAC treatment arm in June or before.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.